Voxmind | $735,203 | (Jun 2, 2026)
Invertix | $1,977,831 | (Jun 2, 2026)
XCENA | $135,000,000 | (Jun 2, 2026)
Certified by Founder
Lodge
NETRIS Pharma
start up
France
- Lyon, Rhône-Alpes
- 20/12/2023
- Series A
- $8,223,000
Our collaborators and partners are driven by a desire to contribute to the development of new ways of fighting cancer. The therapies developed by NETRIS Pharma are based on cellular mechanisms identified by a world-renowned research group.
Located in Léon Bérard Cancer Center (Lyon, France), NETRIS Pharma is a unique model of a biotechnology company integrated within a comprehensive cancer center.
- Industry Pharmaceutical Manufacturing
- Website https://www.netrispharma.com/
- LinkedIn https://www.linkedin.com/company/netris-pharma/about/
Inherent | $50,000,000 | (Jun 2, 2026)
Gray Swan | $40,000,000 | (Jun 2, 2026)
Handshake(UK) | $3,200,000 | (Jun 2, 2026)
Sekai(US) | $26,000,000 | (Jun 2, 2026)
Human Archive (YC W26) | $8,200,000 | (Jun 2, 2026)
Perceptic | $12,000,000 | (Jun 2, 2026)
SpeedLabs | $6,500,000 | (Jun 2, 2026)
MokN | $15,000,000 | (May 29, 2026)
Orebella | Undisclosed Amount | (May 29, 2026)